|
Biological heterogeneity in localized high-risk prostate cancer (LHRPC) from a study of neoadjuvant abiraterone acetate plus leuprolide acetate (LHRHa) versus LHRHa. |
|
|
Honoraria - Johnson & Johnson; Millennium; Sanofi |
Consulting or Advisory Role - Johnson & Johnson; Millennium; Sanofi |
Research Funding - Johnson & Johnson; Medivation; Millennium; Sanofi; Viamet Pharmaceuticals |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
Consulting or Advisory Role - Janssen Research & Development |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
Honoraria - Astellas Pharma; Intuitive Surgical; Myriad Genetics |
Speakers' Bureau - Myriad Genetics |
Research Funding - GenomeDx; Hologic; Janssen |
Travel, Accommodations, Expenses - Astellas Pharma; Intuitive Surgical; Myriad Genetics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
No Relationships to Disclose |
|
|
Employment - Janssen Research & Development |
Leadership - Johnson & Johnson |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Helsinn Healthcare; Johnson & Johnson; Novartis; Pfizer |
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Helsinn Healthcare; Johnson & Johnson; Novartis |
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Helsinn Healthcare; Johnson & Johnson; Novartis; Pfizer |